BioPharm International interviews Bal Bhat, senior director and head of chemistry at Regulus, whose core technology focuses on microRNA drug delivery. Bhat addresses some of the challenges of using microRNA therapeutically and explains Regulus’ conscious decision to use single-stranded microRNA. The possibility of targeting specific tissues using a local delivery system or a packaging molecule is also discussed. Finally, Bhat describes the reactions of potential pharma partners to Regulus’ research data and how the project will move forward.

Related article on Perspectives in MicroRNA Therapeutics